Short answer
IDEAYA Biosciences, Inc. (IDYA) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $208M with net income of $119M.
Q3 2025 key financials · XBRL
- Revenue
- $208M
- Net income
- $119M
- +330.1% YoY · +253.9% QoQ
- Operating margin
- 52.2%
- EPS (diluted)
- $1.35
- +325.0% YoY · +255.2% QoQ
Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) Q3 2025 10-Q on SEC EDGAR. USD.
IDEAYA Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factors this quarter; critical accounting policies unchanged from 10-K filed February 18, 2025
- Operating cash flows improved to positive $19.4M vs negative $125.9M in prior year driven by upfront Servier payment
- Regulatory risk from Servier License Agreement obligations impacting operating cash inflows by $2.2M contract liabilities
- Market risk: significant fluctuations in marketable securities activity with $541.3M maturities vs $371.8M purchases in current period
- Financial risk: reliance on equity financing from at-the-market offerings raising $24.9M, down from $379.9M prior year
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IDEAYA Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.